15 de diciembre de 2019
  • Sábado, 14 de Diciembre
  • Viernes, 13 de Diciembre
  • 27 de noviembre de 2014

    European Cardiologists Highlight Risk of Delayed Diagnosis for Patients with Non-Valvular Atrial Fibrillation (y 2)

    Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Further-more, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model" to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: http://www.daiichisankyo.com . About Daiichi Sankyo Europe Daiichi Sankyo's European base is located in Munich and has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: http://www.daiichi-sankyo.eu . For more information, please contact: Daria Munsel Daiichi Sankyo Europe GmbH

    Tel: +49(89)7808728 (Office)

    Kennesha Baldwin, Director of Media Relations
    Heart Rhythm Society
    Tel: +1-202-464-3476
    kbaldwin@HRSonline.org

    References

    1. AFIB Global Survey of Cardiologists, Harris Poll on behalf of Daiichi Sankyo and the Heart Rhythm Society, July 15 - Aug 07, 27 Nov. (Data on file) - .

    2. Camm, A. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31:2369-429.

    3. Lin, H., Wolf, P. A., Kelly-Hayes, M. & Benjamin, E. J. Stroke Severity in Atrial Fibrillation. Stroke. 1996;27:1760-1764.

    4. Lamassa, M. et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392-8.

    5. Patient.co.uk. Atrial fibrillation. Available at: http://www.patient.co.uk/pdf/4198.pdf . Updated 2012. Last accessed August 2014.

    6. Ball, J et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Card 2013; 167:1807-1824.

    7. Go, A S et al. Heart Disease and Stroke Statistics -- 2013 Update: A Report From the American Heart Association. Circulation. 2013;127:6-245.

    8. Zimerman, Ll. et al. Sociedade Brasileira de Cardiologia [Brazillian guidelines on atrial fibrilation]. Arq Bras Cardiol. 2009;92:1-39.

    9. Inoue, H et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009 Oct 2;137(2):102-7.

    10. World Health Organization. The top 10 causes of death. July 2013. Available at: who.int/mediacentre/factsheets/fs310/en/. Last accessed August 2014.